Universal Health Services plans to acquire Talkspace for $835 million to create a national behavioral health platform that integrates virtual therapy with in-person care. The post Why UHS Is Acquiring Talkspace for $835M appeared first on MedCity News.
Matt Chance and Will Robinson discuss some of the ways LEAD builds on their experience in the high-needs track of the ACO REACH model, which ends in 2026
The virtual health company’s leaders are aiming for mental health revenues from members covered by insurers to reach an annual pace of $100 million by year’s end.
Povetacicept, a Vertex Pharmaceuticals immunology drug designed to block two targets, met the main goal of a Phase 3 clinical trial in the rare kidney disease immunoglobulin A nephropathy. The fusion protein came from Vertex’s acquisition of Alpine Immune Sciences, and analysts say the drug has best-in-class potential. The post Vertex Pharma to Seek Speedy…
La primera llamada llegó justo antes del Día de Acción de Gracias del año pasado. No reconoció el número, pero respondió de todos modos. “La persona dijo que era un oficial del Departamento de Investigaciones Criminales que trabajaba en un caso de tráfico de drogas y lavado de dinero”, recordó la mujer. Parecía saber mucho…
Polypharmacy is a cost and safety problem that is solvable. The right technology platform can reduce it by identifying risky regimens, route specific “stop/switch/consolidate” opportunities to clinicians, and track whether changes stick through refill and adherence patterns. The post Chronic Overmedication: The Polypharmacy Waste and Safety Problem appeared first on MedCity News.
Jonah, de 8 años, se despertó una mañana de mayo con la cara hinchada y dolor de muelas. Se negó a tomar el medicamento para el dolor que su mamá, Geneva Reynolds, trató de darle. No dormía ni comía y lloraba sin parar. En pocos días, Reynolds estaba tan desesperada que ella y su esposo…
The way we measure ALS progression is failing patients. We are entering a new era of ALS therapeutics but still relying on the same blunt instruments of measurement. The post In the Absence of Objective Measures for ALS, Caregivers are the Only Witnesses. We Shouldn’t Have To Be. appeared first on MedCity News.
Valuing early-stage life sciences companies can be complex. Because product development can take several years and be capital intensive, obtaining an accurate valuation is essential to align management’s, the shareholders’, and current and potential investors’ understanding of estimated value. The post Valuing Early-Stage Life Sciences Companies: The Why, the How, and the Impact appeared first…
This brief provides an overview of oral contraception, discusses private insurance and Medicaid coverage, and reviews strategies to promote and expand women’s access to oral contraceptives.